![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » More Manufacturing Woes for DPT as Batch Snafus Delay Imprimis Trial
More Manufacturing Woes for DPT as Batch Snafus Delay Imprimis Trial
August 16, 2013
DPT Laboratories continues to struggle with manufacturing issues, with one drugmaker complaining a pivotal trial has stalled due to DPT’s inability to produce placebos for the trial. Imprimis Pharmaceuticals said Monday that a Phase III clinical trial for its nonsteroidal anti-inflammatory drug Impracor (ketoprofen 10 percent cream) will be delayed because a placebo batch failed and an active batch showed a low specification result.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
21Oct